Sarcoma / 2019 / Article / Tab 2

Research Article

Adjuvant Chemotherapy in Uterine Leiomyosarcoma: Trends and Factors Impacting Usage

Table 2

Multivariate predictors of chemotherapy receipt in nonmetastatic uterine LMS.

VariableOR95% CI

Year of diagnosis
Per year increase1.161.13–1.20<0.0001

Age at diagnosis, y
18–39Ref
40–490.930.67–1.310.6927
50–640.930.67–1.290.6537
65+0.600.38–0.940.0264

Race
WhiteRef
African American0.800.63–1.020.0727
Other1.090.78–1.530.5965

Hispanic
Yes1.340.94–1.910.1112
NoRef

Comorbidities (Charlson/Deyo score)
0Ref
10.930.73–1.180.5332
20.720.37–1.410.3381

Insurance status
PrivateRef
Medicare0.590.42–0.840.0030
Medicaid1.060.77–1.480.7062
None0.920.64–1.300.6265
Other government2.421.04–5.610.0400

Education (% no high school diploma)
≥210.680.48–0.970.0354
13–20.90.580.43–0.790.0005
7–12.90.860.68–1.090.2143
<7Ref

Median household income ($)
<38,0001.491.04–2.130.0282
38,000–47,9991.421.05–1.920.0239
48,000–62,9991.371.07–1.750.0117
>63,000Ref

Location of patient
Large metropolitanRef
Small metropolitan0.920.73–1.150.4570
Suburban1.000.73–1.390.9764
Rural0.690.43–1.100.1146

Hospital volume (cases per year)
0.09Ref
0.18–0.271.000.62–1.610.9964
0.36–0.551.180.74–1.870.4912
0.64–7.271.270.82–1.980.2812

Regional lymph nodes positive
Yes3.831.81–8.090.0004
NoRef

Stage
I0.320.25–0.41<0.0001
II0.380.26–0.56<0.0001
IIIRef

Hormone therapy
Yes0.720.30–1.700.4473
NoRef

Radiation
Yes1.451.17–1.790.0006
NoRef

Oophorectomy
Yes0.920.72–1.190.5395
NoRef